- United States
- /
- Life Sciences
- /
- NasdaqGS:AZTA
The Bull Case For Azenta (AZTA) Could Change Following Profitable Q4 and Upbeat Growth Guidance
Reviewed by Sasha Jovanovic
- Azenta, Inc. recently reported its fourth-quarter earnings, showing US$159.19 million in revenue and a net income of US$47.14 million for the period ended September 30, 2025, reversing a net loss from the previous year.
- One significant insight is Azenta’s transition from loss to profitability on both a net income and earnings per share basis, accompanied by positive guidance for continued organic revenue growth into fiscal year 2026.
- We’ll explore how Azenta’s return to profitability and growth forecast could reshape its investment narrative and future outlook.
These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
Azenta Investment Narrative Recap
To be a shareholder in Azenta today, you would need to believe in the company’s ability to sustain revenue growth through the ongoing expansion of life sciences automation and outsourcing. The company's recent return to profitability and its outlook for organic revenue growth may strengthen the case for continued momentum, but the short-term catalyst remains the pace of recovery in higher-margin capital equipment sales, while the biggest risk continues to be delays from customer budget pressures, which remain largely unchanged after the latest earnings.
Among recent announcements, the fiscal year 2026 revenue growth guidance of 3% to 5% stands out as closely tied to current performance. This communicates management’s focus on incremental top-line growth in the face of sector headwinds and indicates that forecasts of recurring service revenues remain an important watchpoint for short-term results.
In contrast, investors should also be aware that the pace of order recovery for core capital equipment, particularly if customer budget constraints persist, may…
Read the full narrative on Azenta (it's free!)
Azenta's outlook suggests $684.6 million in revenue and $34.5 million in earnings by 2028. This is based on a forecast revenue decline of 0.8% per year and a $202 million increase in earnings from the current level of -$167.5 million.
Uncover how Azenta's forecasts yield a $39.83 fair value, a 12% upside to its current price.
Exploring Other Perspectives
Fair value estimates from two Simply Wall St Community members range from US$36.28 to US$39.83, reflecting different views on Azenta’s earnings and revenue outlook. While market participants see varied upside, recent guidance on organic growth remains central to the company’s forward performance, making it important to compare multiple perspectives.
Explore 2 other fair value estimates on Azenta - why the stock might be worth as much as 12% more than the current price!
Build Your Own Azenta Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Azenta research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Azenta research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Azenta's overall financial health at a glance.
Curious About Other Options?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
- Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:AZTA
Azenta
Provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
Flawless balance sheet and slightly overvalued.
Similar Companies
Market Insights
Community Narratives


Recently Updated Narratives
Astor Enerji will surge with a fair value of $140.43 in the next 3 years
Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.

A case for for IMPACT Silver Corp (TSXV:IPT) to reach USD $4.52 (CAD $6.16) in 2026 (23 bagger in 1 year) and USD $5.76 (CAD $7.89) by 2030
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.
